Delic Labs subsidiary of Delic Holdings Corp DELCF DELC 6X, received a Health Canada 56 research exemption that will allow scientists to conduct research and perform tests on a number of compounds outside of psychedelic mushrooms, including MDMA, LSD, DMT, mescaline and 2C-B. Additionally, Delic Labs has received a Health Canada 56 exemption to acquire 60 grams of psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc., a wholly-owned subsidiary of Psilobrain Therapeutics Inc. Delic Labs' latest exemptions enable the company to develop innovative analytical methods for psychedelic research.
Last year, the lab also applied for a dealer's license with the intent of commercializing psilocybin research and associated intellectual property for medical and research purposes. The company aims to establish consistent quality control standards as more patients and clinicians incorporate psychedelic compounds into treatment plans.
Delic Labs is the engine of innovation for Delic Corp, conducting research and developing new product lines and IP. The company's latest foray into psilocybin research reaffirms its commitment to advancing extraction methods, analytical testing and chemical process development.
"Securing our latest Health Canada 56 exemptions allow us to advance our research efforts as we continue to understand the medical applications of psychedelic compounds," stated Dr. Markus Roggen, co-founder of Delic Labs. "Psychedelics show tremendous promise as a new class of therapeutics, and Delic Labs is taking extensive measures to establish best practices in developing and manufacturing these potential treatments. We look forward to exploring these novel compounds with the goal of commercializing the research once our dealer's license is secured."
Photo: Courtesy of Pretty Drugthings on Unsplash
To hear more about the important and fascinating scientific advances and meet face-to-face with some of this nascent industry’s professionals & market leaders, join us at the Benzinga Psychedelics Capital Conference on April 19, 2022 at the Fontainebleau Miami Beach where we are bringing together leaders of the largest publicly-traded Psychedelics companies with investors from across North America.
Tickets for this first-of-its-kind gathering are still available here.
Related News
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.